Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.

التفاصيل البيبلوغرافية
العنوان:	Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
المؤلفون:	García MJ; Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain., Rivero M; Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain., Fernández-Clotet A; Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain., de Francisco R; Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Sicilia B; IBD Unit, Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain., Mesonero F; Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., de Castro ML; Gastroenterology Department, Hospital Álvaro Cunqueiro, Vigo, Spain., Casanova MJ; Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Bertoletti F; Gastroenterology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain., García-Alonso FJ; Gastroenterology Department, Hospital Universitario Río Hortega, Valladolid, Spain., López-García A; Gastroenterology Department, Hospital del Mar, Barcelona, Barcelona, Spain., Vicente R; Gastroenterology Department, Hospital Universitario Miguel Servet, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Zaragoza, Spain., Calvet X; Gastroenterology Department, Consorci Corporació Sanitària Parc Taulí, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Sabadell, Spain., Barreiro-de Acosta M; Gastroenterology Department, Hospital Universitario Clínico de Santiago, Santiago de Compostela, Spain., Ferrer Rosique J; Gastroenterology Department, Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain., Varela Trastoy P; Gastroenterology Department, Hospital Universitario de Cabueñes, Gijón, Spain., Nuñez A; Gastroenterology Department, Hospital Universitario de Salamanca, Salamanca, Spain., Ricart E; Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain., Riestra S; Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Arias García L; IBD Unit, Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain., Rodríguez M; Gastroenterology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Arranz L; Gastroenterology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain., Pajares R; Gastroenterology Department, Hospital Universitario Infanta Sofía, Madrid, Spain., Mena R; Gastroenterology Department, Consorci Sanitari de Terrasa, Barcelona, Spain., Calafat M; Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Spain., Camo P; Gastroenterology Department, Hospital General San Jorge, Huesca, Spain., Bermejo F; Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain., Ponferrada Á; Gastroenterology Department, Hospital Universitario Infanta Leonor, Madrid, Spain., Madrigal RE; Gastroenterology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Llaó J; Gastroenterology Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain., Sesé E; Gastroenterology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain., Sánchez E; Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Pineda Mariño JR; Gastroenterology Department, Hospital Álvaro Cunqueiro, Vigo, Spain., González Muñoza C; Gastroenterology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain., Carbajo López AY; Gastroenterology Department, Hospital Universitario Río Hortega, Valladolid, Spain., Julián AB; Gastroenterology Department, Hospital Universitario Miguel Servet, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Zaragoza, Spain., Villoria Ferrer A; Gastroenterology Department, Consorci Corporació Sanitària Parc Taulí, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Sabadell, Spain., Baston-Rey I; Gastroenterology Department, Hospital Universitario Clínico de Santiago, Santiago de Compostela, Spain., Jara L; Gastroenterology Department, Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain., Almela P; Gastroenterology Department, Hospital General Universitario de Castellón, Castellón, Spain., Codesido L; Gastroenterology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., de la Maza S; Gastroenterology Department, Hospital Universitario de Basurto, Bilbao, Spain., Leal C; Gastroenterology Department, Consorci Hospitalari de Vic, Vic, Spain., Caballol B; Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain., Pérez-Martínez I; Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., Vinuesa Campo R; IBD Unit, Gastroenterology Department, Hospital Universitario de Burgos, Burgos, Spain., Crespo J; Gastroenterology and Hepatology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Instituto de Investigación Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain., Domènech E; Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Spain., Chaparro M; Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Gisbert JP; Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
المصدر:	Journal of Crohn's & colitis [J Crohns Colitis] 2024 Jan 27; Vol. 18 (1), pp. 65-74.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN: 1876-4479 (Electronic) Linking ISSN: 18739946 NLM ISO Abbreviation: J Crohns Colitis Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2015- : Oxford : Oxford University Press Original Publication: Amsterdam : Elsevier Science
مواضيع طبية MeSH:	Ustekinumab/therapeutic use , Crohn Disease/drug therapy , Antibodies, Monoclonal, Humanized*, Humans ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Remission Induction ; Tumor Necrosis Factor-alpha ; Registries ; Treatment Outcome ; Retrospective Studies
مستخلص:	Background: Both vedolizumab and ustekinumab are approved for the management of Crohn's disease [CD]. Data on which one would be the most beneficial option when anti-tumour necrosis factor [anti-TNF] agents fail are limited. Aims: To compare the durability, effectiveness, and safety of vedolizumab and ustekinumab after anti-TNF failure or intolerance in CD. Methods: CD patients from the ENEIDA registry who received vedolizumab or ustekinumab after anti-TNF failure or intolerance were included. Durability and effectiveness were evaluated in both the short and the long term. Effectiveness was defined according to the Harvey-Bradshaw index [HBI]. The safety profile was compared between the two treatments. The propensity score was calculated by the inverse probability weighting method to balance confounder factors. Results: A total of 835 patients from 30 centres were included, 207 treated with vedolizumab and 628 with ustekinumab. Dose intensification was performed in 295 patients. Vedolizumab [vs ustekinumab] was associated with a higher risk of treatment discontinuation (hazard ratio [HR] 2.55, 95% confidence interval [CI]: 2.02-3.21), adjusted by corticosteroids at baseline [HR 1.27; 95% CI: 1.00-1.62], moderate-severe activity in HBI [HR 1.79; 95% CI: 1.20-2.48], and high levels of C-reactive protein at baseline [HR 1.06; 95% CI: 1.02-1.10]. The inverse probability weighting method confirmed these results. Clinical response, remission, and corticosteroid-free clinical remission were higher with ustekinumab than with vedolizumab. Both drugs had a low risk of adverse events with no differences between them. Conclusion: In CD patients who have failed anti-TNF agents, ustekinumab seems to be superior to vedolizumab in terms of durability and effectiveness in clinical practice. The safety profile is good and similar for both treatments. (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
معلومات مُعتمدة:	Spanish Working Group in Crohn's Disease and Ulcerative Colitis
فهرسة مساهمة:	Keywords: Crohn’s disease; durability; effectiveness; ustekinumab; vedolizumab
المشرفين على المادة:	FU77B4U5Z0 (Ustekinumab) 9RV78Q2002 (vedolizumab) 0 (Tumor Necrosis Factor Inhibitors) 0 (Tumor Necrosis Factor-alpha) 0 (Antibodies, Monoclonal, Humanized)
تواريخ الأحداث:	Date Created: 20230731 Date Completed: 20240129 Latest Revision: 20240129
رمز التحديث:	20240129
DOI:	10.1093/ecco-jcc/jjad124
PMID:	37522878
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1876-4479
DOI:	10.1093/ecco-jcc/jjad124